SEARCH:   Advanced

Blood, 1 July 2008, Vol. 112, No. 1, pp. 45-52. Prepublished online as a Blood First Edition Paper on April 28, 2008; DOI 10.1182/blood-2008-01-134858. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-01-134858v1 112/1/45    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Rollison, D. E. Articles by List, A. F. PubMed PubMed Citation Articles by Rollison, D. E. Articles by List, A. F. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs Dana E. Rollison1, Nadia Howlader2, Martyn T. Smith3, Sara S. Strom4, William D. Merritt5, Lynn A. Ries6, Brenda K. Edwards6, and Alan F. List7 1 Cancer Prevention and Control Division, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; 2 Contractor to the National Cancer Institute (NCI), Bethesda, MD; 3 Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley; 4 Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston; 5 Cancer Therapy Evaluation Program, NCI, Bethesda, MD; 6 Surveillance Research Program, NCI, Bethesda, MD; and 7 Hematologic Malignancy Division, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Reporting of myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based cancer registries in the United States was initiated in 2001. In this first analysis of data from the North American Association of Central Cancer Registries (NAACCR), encompassing 82% of the US population, we evaluated trends in MDS and CMD incidence, estimated case numbers for the entire United States, and assessed trends in diagnostic recognition and reporting. Based on more than 40 000 observations, average annual age-adjusted incidence rates of MDS and CMD for 2001 through 2003 were 3.3 and 2.1 per 100 000, respectively. Incidence rates increased with age for both MDS and CMD (P < .05) and were highest among whites and non-Hispanics. Based on follow-up data through 2004 from the Surveillance, Epidemiology, and End Results (SEER) Program, overall relative 3-year survival rates for MDS and CMD were 45% and 80%, respectively, with males experiencing poorer survival than females. Applying the observed age-specific incidence rates to US Census population estimates, approximately 9700 patients with MDS and 6300 patients with CMD were estimated for the entire United States in 2004. MDS incidence rates significantly increased with calendar year in 2001 through 2004, and only 4% of patients were reported to registries by physicians' offices. Thus, MDS disease burden in the United States may be underestimated. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020